查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1551334

到 2030 年抗治療性憂鬱症市場預測：按治療方式、分銷管道、最終用戶和地區進行的全球分析

Treatment-Resistant Depression Market Forecasts to 2030 - Global Analysis by Treatment Modality, Distribution Channel, End User and By Geography
出版日期: | 出版商: Stratistics Market Research Consulting | 英文 200+ Pages | 商品交期: 2-3個工作天內

價格

根據 Stratistics MRC 的數據，2024 年全球抗治療性憂鬱症市場規模為 21 億美元，預計預測期內複合年成長率為 11.8%，到 2030 年將達到 41 億美元。

抗治療性憂鬱症(TRD) 是重度憂鬱症的一種形式，對至少兩種足夠劑量和持續時間的抗憂鬱症治療沒有充分反應。約有30%的憂鬱症患者受到影響。 TRD 的特點是儘管採取了標準干預措施，但仍存在持續的憂鬱症狀，並且通常需要替代策略，例如藥物、心理治療、腦刺激技術和新療法的組合。 TRD 對患者和臨床醫生來說是一個重大挑戰，與非持久性憂鬱症相比，它會導致功能障礙增加、醫療保健費用增加以及自殺行為的風險增加。

根據 2024 年 5 月發表在《美國精神病學雜誌》上的研究資料，美國接受藥物治療的重度憂鬱症(MDD) 12 個月盛行率估計為 890 萬人。

憂鬱症盛行率增加

全球憂鬱症盛行率的增加是抗治療性憂鬱症市場的主要促進因素。根據世界衛生組織 (WHO) 統計，全球有超過 3 億人患有憂鬱症。隨著憂鬱症患者數量的增加，抗治療性憂鬱症患者的數量也增加。患者數量的增加為先進治療方法創造了更大的市場，並推動了研究和開發，以找到針對這種困難疾病的更有效的治療方法。

昂貴的治療費用

抗治療性憂鬱症的高昂治療費用是市場成長的主要限制因素。氯胺酮輸注、經顱磁刺激和esketamine滴鼻劑等較新的治療方法價格昂貴，而且通常不在保險範圍內。例如，氯胺酮輸註一個療程可能花費數千美元。這些高昂的自付費用可能會限制許多患者獲得治療，阻礙新治療方法的採用，並減緩市場擴張。

新療法的研發管線

一系列針對抗治療性憂鬱症的新療法提供了巨大的市場機會。幾種有前景的化合物正處於後期臨床試驗中，包括裸蓋菇素等致幻藥物、新型麩胺酸促效劑和創新藥物組合。例如，COMP360（裸蓋菇素療法）在 2 期試驗中顯示出正面的結果。如果這些新療法有可能獲得核准，我們可以透過擴大治療選擇、改善治療結果和解決抗治療性患者未滿足的需求來預期市場成長。

嚴格的法規環境

FDA 等監管機構在核准新藥，特別是具有新穎作用機制的核准時，需要大量的臨床試驗資料和安全性資料。這個嚴格的過程導致新藥上市的延遲、開發成本的增加以及潛在的失敗。監管障礙可能會抑制對創新治療方法的投資，並減緩新治療方法的推出速度。

COVID-19 的影響：

COVID-19 大流行抗治療性憂鬱症市場產生了重大影響。禁閉和社會隔離導致憂鬱症和焦慮增加，病例數可能還會增加。同時，醫療保健取得和臨床試驗的中斷正在影響治療提供和研究進展。然而，大流行加速了遠端醫療和數位心理健康解決方案的採用，為治療提供和市場成長開闢了新途徑。

零售藥房業務預計將在預測期內成為最大的業務

預計零售藥房領域將在預測期內主導抗治療性憂鬱症市場。零售藥局為抗治療性憂鬱症患者提供便利的處方藥取得途徑。零售藥局在配藥、病患教育和藥物依從性支持方面發揮重要作用。透過零售管道擴大獲得新型抗憂鬱症和輔助性治療，促進了這一領域的成長。此外，憂鬱症門診治療的趨勢和全球零售藥局連鎖店的增加進一步支持了這一領域的擴張。

神經刺激治療領域預計在預測期內複合年成長率最高

在抗治療性憂鬱症市場中，神經刺激療法預計將具有最高的複合年成長率。這種成長是由擴大採用非侵入性腦刺激技術（例如經顱磁刺激（TMS）和電休克治療（ECT））所推動的。這些方法為對傳統藥物治療沒有反應的患者提供了替代治療選擇。越來越多的證據支持神經刺激的有效性以及提高安全性和耐受性的技術進步正在促進這一領域的快速擴張。

佔比最大的地區：

預計北美地區將在預測期內主導抗治療性憂鬱症市場。北美的優勢歸因於憂鬱症盛行率較高、醫療基礎設施完善以及較早採用新治療方法等因素。該地區還受益於大量的研發投資、主要市場參與者的存在以及優惠的報銷政策。此外，人們對心理健康的認知不斷提高，對創新治療方法的接受度也不斷提高，這也有助於北美市場的領先地位。

複合年成長率最高的地區：

在預測期內，亞太地區抗治療性憂鬱症市場預計將快速成長。這一成長是由心理健康意識增強、醫療基礎設施改善和醫療支出增加等因素所推動的。中國和印度等國家人口眾多，憂鬱症盛行率不斷上升，因此存在巨大的市場機會。此外，製藥公司向亞太地區的擴張以及政府不斷採取的解決心理健康問題的措施也促進了亞太市場的快速成長。

免費客製化服務

訂閱此報告的客戶可以存取以下免費自訂選項之一：

  • 公司簡介
    • 其他市場參與者的綜合分析（最多 3 家公司）
    • 主要企業SWOT分析（最多3家企業）
  • 區域分割
    • 根據客戶興趣對主要國家的市場估計、預測和複合年成長率（註：基於可行性檢查）
  • 競爭標基準化分析
    • 根據產品系列、地理分佈和策略聯盟對主要企業基準化分析

目錄

第1章執行摘要

第2章 前言

  • 概述
  • 相關利益者
  • 調查範圍
  • 調查方法
    • 資料探勘
    • 資料分析
    • 資料檢驗
    • 研究途徑
  • 研究資訊來源
    • 主要研究資訊來源
    • 二次研究資訊來源
    • 先決條件

第3章市場趨勢分析

  • 促進因素
  • 抑制因素
  • 機會
  • 威脅
  • 最終用戶分析
  • 新興市場
  • COVID-19 的影響

第4章波特五力分析

  • 供應商的議價能力
  • 買方議價能力
  • 替代品的威脅
  • 新進入者的威脅
  • 競爭公司之間的敵對關係

第5章全球抗治療性憂鬱症：依治療方式分類

  • 藥物治療
    • 選擇性血清素再回收抑制劑（SSRI）
    • 正腎上腺素再回收抑制劑(SNRI)
    • 三環抗憂鬱藥物（TCA）
    • 單胺氧化酵素抑制劑 (MAOIs)
    • 抗精神病藥
    • 情緒穩定劑
    • 氯胺酮和esketamine
    • 其他藥物
  • 心理治療
    • 認知行為治療（CBT）
    • 人際關係治療（IPT）
    • 心理動力療法
    • 其他心理治療
  • 神經刺激
    • 經顱磁刺激（TMS）
    • 深部腦部刺激（DBS）
    • 迷走神經刺激 (VNS)
    • 電痙攣治療 (ECT)
    • 其他神經刺激療法
  • 聯合治療

第6章 全球抗治療性憂鬱症：依通路分類

  • 醫院藥房
  • 零售藥房
  • 網路藥房
  • 遠端醫療平台

第7章 全球抗治療性憂鬱症：依最終使用者分類

  • 醫院
  • 專科診所
  • 門診
  • 研究所
  • 其他最終用戶

第8章全球抗治療性憂鬱症：按地區

  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 德國
    • 英國
    • 義大利
    • 法國
    • 西班牙
    • 其他歐洲國家
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 紐西蘭
    • 韓國
    • 其他亞太地區
  • 南美洲
    • 阿根廷
    • 巴西
    • 智利
    • 南美洲其他地區
  • 中東/非洲
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 卡達
    • 南非
    • 其他中東和非洲

第9章 主要進展

  • 合約、夥伴關係、合作和合資企業
  • 收購和合併
  • 新產品發布
  • 業務拓展
  • 其他關鍵策略

第 10 章 公司概況

  • AstraZeneca
  • Pfizer Inc.
  • GlaxoSmithKline plc
  • Eli Lilly and Company
  • Johnson & Johnson
  • Bristol-Myers Squibb Company
  • Forest Laboratories
  • Vistagen Therapeutics, Inc.
  • Novartis
  • AbbVie Inc.
  • H. Lundbeck A/S
  • Sandoz International GmbH
  • Otsuka Pharmaceutical Co., Ltd.
  • Par Pharmaceutical
  • Mylan NV
  • Aurobindo Pharma
  • Teva Pharmaceutical Industries Ltd.
Product Code: SMRC27117

According to Stratistics MRC, the Global Treatment-Resistant Depression Market is accounted for $2.1 billion in 2024 and is expected to reach $4.1 billion by 2030 growing at a CAGR of 11.8% during the forecast period. Treatment-resistant depression (TRD) is a form of major depressive disorder that does not respond adequately to at least two different antidepressant treatments of sufficient dose and duration. It affects approximately 30% of people with depression. TRD is characterized by persistent depressive symptoms despite standard interventions, often requiring alternative strategies like medication combinations, psychotherapy, brain stimulation techniques, or novel therapies. It poses significant challenges for patients and clinicians, leading to increased functional impairment, higher healthcare costs, and a greater risk of suicidal behavior compared to non-resistant depression.

According to data from a study published in the American Journal of Psychiatry in May 2024, the estimated 12-month prevalence of medication-treated major depressive disorder (MDD) in the United States was 8.9 million adults.

Market Dynamics:

Driver:

Increasing prevalence of depression

The rising prevalence of depression globally is a key driver for the treatment-resistant depression market. According to the World Health Organization, over 300 million people suffer from depression worldwide. As the number of depression cases increases, so does the subset of patients with treatment-resistant depression. This growing patient pool creates a larger market for advanced therapies and drives research and development efforts to find more effective treatments for this challenging condition.

Restraint:

High cost of treatment

The high cost of treatment for treatment-resistant depression poses a significant restraint on market growth. Novel therapies like ketamine infusions, transcranial magnetic stimulation, and esketamine nasal sprays are expensive and often not covered by insurance. For example, a course of ketamine infusions can cost thousands of dollars. These high out-of-pocket costs limit access to treatment for many patients and hinder widespread adoption of newer therapies, potentially slowing market expansion.

Opportunity:

Pipeline of novel therapies

The robust pipeline of novel therapies for treatment-resistant depression presents a significant market opportunity. Several promising compounds are in late-stage clinical trials, including psychedelics like psilocybin, new glutamatergic agents, and innovative drug combinations. For instance, COMP360 (psilocybin therapy) has shown positive results in phase 2 trials. The potential approval of these novel treatments could expand treatment options, improve outcomes, and drive market growth by addressing the unmet needs of treatment-resistant patients.

Threat:

Stringent regulatory environment

Regulatory agencies like the FDA require extensive clinical trial data and safety profiles for new drug approvals, especially for novel mechanisms of action. This rigorous process can lead to delays, increased development costs, and potential failures in bringing new treatments to market. The regulatory hurdles may discourage investment in innovative therapies and slow the pace of new treatment options becoming available.

Covid-19 Impact:

The COVID-19 pandemic has significantly impacted the treatment-resistant depression market. Lockdowns and social isolation have led to increased rates of depression and anxiety, potentially expanding the patient pool. Simultaneously, disruptions in healthcare access and clinical trials have affected treatment delivery and research progress. However, the pandemic has also accelerated the adoption of telemedicine and digital mental health solutions, opening new avenues for treatment delivery and market growth.

The retail pharmacies segment is expected to be the largest during the forecast period

The retail pharmacies segment is projected to dominate the treatment-resistant depression market during the forecast period. Retail pharmacies offer convenient access to prescription medications for patients with treatment-resistant depression. They play a crucial role in medication dispensing, patient education, and adherence support. The increasing availability of novel antidepressants and adjunctive therapies through retail channels contributes to this segment's growth. Additionally, the trend towards outpatient management of depression and the rising number of retail pharmacy chains globally further drive the expansion of this segment.

The neurostimulation segment is expected to have the highest CAGR during the forecast period

The neurostimulation segment is anticipated to experience the highest CAGR in the treatment-resistant depression market. This growth is driven by the increasing adoption of non-invasive brain stimulation techniques like transcranial magnetic stimulation (TMS) and electroconvulsive therapy (ECT). These methods offer alternative treatment options for patients who have not responded to traditional pharmacotherapy. The growing body of evidence supporting the efficacy of neurostimulation techniques, coupled with technological advancements improving their safety and tolerability, contributes to the rapid expansion of this segment.

Region with largest share:

During the forecast period, the North American region is expected to dominate the treatment-resistant depression market. North America's dominance can be attributed to factors such as the high prevalence of depression, well-established healthcare infrastructure, and early adoption of novel therapies. The region also benefits from significant research and development investments, the presence of key market players, and favorable reimbursement policies. Additionally, increased awareness about mental health and growing acceptance of innovative treatments contribute to North America's leading position in the market.

Region with highest CAGR:

During the forecast period, the Asia Pacific region is expected to witness rapid growth in the treatment-resistant depression market. This growth is driven by factors such as increasing awareness about mental health, improving healthcare infrastructure, and rising healthcare expenditure. The large population base and growing prevalence of depression in countries like China and India present significant market opportunities. Additionally, the expansion of pharmaceutical companies into the region and increasing government initiatives to address mental health issues contribute to the rapid market growth in Asia Pacific.

Key players in the market

Some of the key players in Treatment-Resistant Depression market include AstraZeneca, Pfizer Inc., GlaxoSmithKline plc, Eli Lilly and Company, Johnson & Johnson, Bristol-Myers Squibb Company, Forest Laboratories, Vistagen Therapeutics, Inc., Novartis, AbbVie Inc., H. Lundbeck A/S, Sandoz International GmbH, Otsuka Pharmaceutical Co., Ltd., Par Pharmaceutical, Mylan N.V., Aurobindo Pharma, and Teva Pharmaceutical Industries Ltd.

Key Developments:

In August 2024, AbbVie announced that it has completed its acquisition of Cerevel Therapeutics. With the completion of the acquisition, Cerevel is now part of AbbVie. "AbbVie's acquisition of Cerevel strengthens our foundation in neuroscience and positions us to deliver sustainable long-term performance into the next decade and beyond," said Robert A. Michael, chief executive officer, AbbVie.

In July 2024, Johnson & Johnson announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) seeking approval of SPRAVATO(R) (esketamine) CIII nasal spray as a monotherapy for adults living with treatment-resistant depression (TRD). Nearly 30 percent of the estimated 280 million people worldwide living with major depressive disorder (MDD) have TRD,1 which occurs when there is an inadequate response to two or more oral antidepressants during the same depressive episode.

In December 2022, AbbVie announced that the U.S. Food and Drug Administration (FDA) has approved VRAYLAR(R) (cariprazine) as an adjunctive therapy to antidepressants for the treatment of major depressive disorder (MDD) in adults. Supported by clinical data demonstrating efficacy and well-established tolerability, this additional indication provides a new option for adults who have a partial response to the treatment of an antidepressant.

Treatment Modalities Covered:

  • Pharmacotherapy
  • Psychotherapy
  • Neurostimulation
  • Combination Therapies

Distribution Channels Covered:

  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies
  • Telemedicine Platforms

End Users Covered:

  • Hospitals
  • Specialty Clinics
  • Outpatient Clinics
  • Research Institutes
  • Other End Users

Regions Covered:

  • North America
    • US
    • Canada
    • Mexico
  • Europe
    • Germany
    • UK
    • Italy
    • France
    • Spain
    • Rest of Europe
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • New Zealand
    • South Korea
    • Rest of Asia Pacific
  • South America
    • Argentina
    • Brazil
    • Chile
    • Rest of South America
  • Middle East & Africa
    • Saudi Arabia
    • UAE
    • Qatar
    • South Africa
    • Rest of Middle East & Africa

What our report offers:

  • Market share assessments for the regional and country-level segments
  • Strategic recommendations for the new entrants
  • Covers Market data for the years 2022, 2023, 2024, 2026, and 2030
  • Market Trends (Drivers, Constraints, Opportunities, Threats, Challenges, Investment Opportunities, and recommendations)
  • Strategic recommendations in key business segments based on the market estimations
  • Competitive landscaping mapping the key common trends
  • Company profiling with detailed strategies, financials, and recent developments
  • Supply chain trends mapping the latest technological advancements

Free Customization Offerings:

All the customers of this report will be entitled to receive one of the following free customization options:

  • Company Profiling
    • Comprehensive profiling of additional market players (up to 3)
    • SWOT Analysis of key players (up to 3)
  • Regional Segmentation
    • Market estimations, Forecasts and CAGR of any prominent country as per the client's interest (Note: Depends on feasibility check)
  • Competitive Benchmarking
    • Benchmarking of key players based on product portfolio, geographical presence, and strategic alliances

Table of Contents

1 Executive Summary

2 Preface

  • 2.1 Abstract
  • 2.2 Stake Holders
  • 2.3 Research Scope
  • 2.4 Research Methodology
    • 2.4.1 Data Mining
    • 2.4.2 Data Analysis
    • 2.4.3 Data Validation
    • 2.4.4 Research Approach
  • 2.5 Research Sources
    • 2.5.1 Primary Research Sources
    • 2.5.2 Secondary Research Sources
    • 2.5.3 Assumptions

3 Market Trend Analysis

  • 3.1 Introduction
  • 3.2 Drivers
  • 3.3 Restraints
  • 3.4 Opportunities
  • 3.5 Threats
  • 3.6 End User Analysis
  • 3.7 Emerging Markets
  • 3.8 Impact of Covid-19

4 Porters Five Force Analysis

  • 4.1 Bargaining power of suppliers
  • 4.2 Bargaining power of buyers
  • 4.3 Threat of substitutes
  • 4.4 Threat of new entrants
  • 4.5 Competitive rivalry

5 Global Treatment-Resistant Depression Market, By Treatment Modality

  • 5.1 Introduction
  • 5.2 Pharmacotherapy
    • 5.2.1 Selective Serotonin Reuptake Inhibitors (SSRIs)
    • 5.2.2 Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs)
    • 5.2.3 Tricyclic Antidepressants (TCAs)
    • 5.2.4 Monoamine Oxidase Inhibitors (MAOIs)
    • 5.2.5 Antipsychotics
    • 5.2.6 Mood Stabilizers
    • 5.2.7 Ketamine and Esketamine
    • 5.2.8 Other Pharmacotherapies
  • 5.3 Psychotherapy
    • 5.3.1 Cognitive Behavioral Therapy (CBT)
    • 5.3.2 Interpersonal Therapy (IPT)
    • 5.3.3 Psychodynamic Therapy
    • 5.3.4 Other Psychotherapies
  • 5.4 Neurostimulation
    • 5.4.1 Transcranial Magnetic Stimulation (TMS)
    • 5.4.2 Deep Brain Stimulation (DBS)
    • 5.4.3 Vagus Nerve Stimulation (VNS)
    • 5.4.4 Electroconvulsive Therapy (ECT)
    • 5.4.5 Other Neurostimulation Therapies
  • 5.5 Combination Therapies

6 Global Treatment-Resistant Depression Market, By Distribution Channel

  • 6.1 Introduction
  • 6.2 Hospital Pharmacies
  • 6.3 Retail Pharmacies
  • 6.4 Online Pharmacies
  • 6.5 Telemedicine Platforms

7 Global Treatment-Resistant Depression Market, By End User

  • 7.1 Introduction
  • 7.2 Hospitals
  • 7.3 Specialty Clinics
  • 7.4 Outpatient Clinics
  • 7.5 Research Institutes
  • 7.6 Other End Users

8 Global Treatment-Resistant Depression Market, By Geography

  • 8.1 Introduction
  • 8.2 North America
    • 8.2.1 US
    • 8.2.2 Canada
    • 8.2.3 Mexico
  • 8.3 Europe
    • 8.3.1 Germany
    • 8.3.2 UK
    • 8.3.3 Italy
    • 8.3.4 France
    • 8.3.5 Spain
    • 8.3.6 Rest of Europe
  • 8.4 Asia Pacific
    • 8.4.1 Japan
    • 8.4.2 China
    • 8.4.3 India
    • 8.4.4 Australia
    • 8.4.5 New Zealand
    • 8.4.6 South Korea
    • 8.4.7 Rest of Asia Pacific
  • 8.5 South America
    • 8.5.1 Argentina
    • 8.5.2 Brazil
    • 8.5.3 Chile
    • 8.5.4 Rest of South America
  • 8.6 Middle East & Africa
    • 8.6.1 Saudi Arabia
    • 8.6.2 UAE
    • 8.6.3 Qatar
    • 8.6.4 South Africa
    • 8.6.5 Rest of Middle East & Africa

9 Key Developments

  • 9.1 Agreements, Partnerships, Collaborations and Joint Ventures
  • 9.2 Acquisitions & Mergers
  • 9.3 New Product Launch
  • 9.4 Expansions
  • 9.5 Other Key Strategies

10 Company Profiling

  • 10.1 AstraZeneca
  • 10.2 Pfizer Inc.
  • 10.3 GlaxoSmithKline plc
  • 10.4 Eli Lilly and Company
  • 10.5 Johnson & Johnson
  • 10.6 Bristol-Myers Squibb Company
  • 10.7 Forest Laboratories
  • 10.8 Vistagen Therapeutics, Inc.
  • 10.9 Novartis
  • 10.10 AbbVie Inc.
  • 10.11 H. Lundbeck A/S
  • 10.12 Sandoz International GmbH
  • 10.13 Otsuka Pharmaceutical Co., Ltd.
  • 10.14 Par Pharmaceutical
  • 10.15 Mylan N.V.
  • 10.16 Aurobindo Pharma
  • 10.17 Teva Pharmaceutical Industries Ltd.

List of Tables

  • Table 1 Global Treatment-Resistant Depression Market Outlook, By Region (2022-2030) ($MN)
  • Table 2 Global Treatment-Resistant Depression Market Outlook, By Treatment Modality (2022-2030) ($MN)
  • Table 3 Global Treatment-Resistant Depression Market Outlook, By Pharmacotherapy (2022-2030) ($MN)
  • Table 4 Global Treatment-Resistant Depression Market Outlook, By Selective Serotonin Reuptake Inhibitors (SSRIs) (2022-2030) ($MN)
  • Table 5 Global Treatment-Resistant Depression Market Outlook, By Serotonin-Norepinephrine Reuptake Inhibitors (SNRIs) (2022-2030) ($MN)
  • Table 6 Global Treatment-Resistant Depression Market Outlook, By Tricyclic Antidepressants (TCAs) (2022-2030) ($MN)
  • Table 7 Global Treatment-Resistant Depression Market Outlook, By Monoamine Oxidase Inhibitors (MAOIs) (2022-2030) ($MN)
  • Table 8 Global Treatment-Resistant Depression Market Outlook, By Antipsychotics (2022-2030) ($MN)
  • Table 9 Global Treatment-Resistant Depression Market Outlook, By Mood Stabilizers (2022-2030) ($MN)
  • Table 10 Global Treatment-Resistant Depression Market Outlook, By Ketamine and Esketamine (2022-2030) ($MN)
  • Table 11 Global Treatment-Resistant Depression Market Outlook, By Other Pharmacotherapies (2022-2030) ($MN)
  • Table 12 Global Treatment-Resistant Depression Market Outlook, By Psychotherapy (2022-2030) ($MN)
  • Table 13 Global Treatment-Resistant Depression Market Outlook, By Cognitive Behavioral Therapy (CBT) (2022-2030) ($MN)
  • Table 14 Global Treatment-Resistant Depression Market Outlook, By Interpersonal Therapy (IPT) (2022-2030) ($MN)
  • Table 15 Global Treatment-Resistant Depression Market Outlook, By Psychodynamic Therapy (2022-2030) ($MN)
  • Table 16 Global Treatment-Resistant Depression Market Outlook, By Other Psychotherapies (2022-2030) ($MN)
  • Table 17 Global Treatment-Resistant Depression Market Outlook, By Neurostimulation (2022-2030) ($MN)
  • Table 18 Global Treatment-Resistant Depression Market Outlook, By Transcranial Magnetic Stimulation (TMS) (2022-2030) ($MN)
  • Table 19 Global Treatment-Resistant Depression Market Outlook, By Deep Brain Stimulation (DBS) (2022-2030) ($MN)
  • Table 20 Global Treatment-Resistant Depression Market Outlook, By Vagus Nerve Stimulation (VNS) (2022-2030) ($MN)
  • Table 21 Global Treatment-Resistant Depression Market Outlook, By Electroconvulsive Therapy (ECT) (2022-2030) ($MN)
  • Table 22 Global Treatment-Resistant Depression Market Outlook, By Other Neurostimulation Therapies (2022-2030) ($MN)
  • Table 23 Global Treatment-Resistant Depression Market Outlook, By Combination Therapies (2022-2030) ($MN)
  • Table 24 Global Treatment-Resistant Depression Market Outlook, By Distribution Channel (2022-2030) ($MN)
  • Table 25 Global Treatment-Resistant Depression Market Outlook, By Hospital Pharmacies (2022-2030) ($MN)
  • Table 26 Global Treatment-Resistant Depression Market Outlook, By Retail Pharmacies (2022-2030) ($MN)
  • Table 27 Global Treatment-Resistant Depression Market Outlook, By Online Pharmacies (2022-2030) ($MN)
  • Table 28 Global Treatment-Resistant Depression Market Outlook, By Telemedicine Platforms (2022-2030) ($MN)
  • Table 29 Global Treatment-Resistant Depression Market Outlook, By End User (2022-2030) ($MN)
  • Table 30 Global Treatment-Resistant Depression Market Outlook, By Hospitals (2022-2030) ($MN)
  • Table 31 Global Treatment-Resistant Depression Market Outlook, By Specialty Clinics (2022-2030) ($MN)
  • Table 32 Global Treatment-Resistant Depression Market Outlook, By Outpatient Clinics (2022-2030) ($MN)
  • Table 33 Global Treatment-Resistant Depression Market Outlook, By Research Institutes (2022-2030) ($MN)
  • Table 34 Global Treatment-Resistant Depression Market Outlook, By Other End Users (2022-2030) ($MN)

Note: Tables for North America, Europe, APAC, South America, and Middle East & Africa Regions are also represented in the same manner as above.